Navigation Links
Blue Dye Halts Worsening Paralysis in Animal Study
Date:7/28/2009

Discovery could lead to new treatments for people with spine injuries

TUESDAY, July 28 (HealthDay News) -- The food additive that makes M&Ms and Gatorade blue may help prevent the secondary damage that occurs after a spinal cord injury, a new study suggests.

Researchers say that the dye, called Brilliant Blue G (BBG), stops the cascade of molecular events that can expand the area of injury and permanently worsen paralysis.

This finding builds on landmark research that detailed how ATP, the vital energy source that keeps the body's cells alive, pours into the area around a spinal cord injury, killing off healthy and uninjured cells. This previous research also laid out a potential way to stop secondary spinal injury: use oxidized ATP to block the ATP, according to background information provided in a news release from the University of Rochester.

Rats with damaged spinal cords that were injected with oxidized ATP recovered much of their limb function and were able to effectively, if not gracefully, walk again, the earlier research found.

The new study has found a compound that does the same thing, and it doesn't have to be injected directly into the injured spinal cord to work, the study authors explain in their report, published online in this week's issue of the Proceedings of the National Academy of Sciences.

"While we achieved great results when oxidized ATP was injected directly into the spinal cord, this method would not be practical for use with spinal cord-injured patients," said lead researcher Dr. Maiken Nedergaard, a professor of neurosurgery and director of the Center for Translational Neuromedicine at the University of Rochester Medical Center.

"First, no one wants to put a needle into a spinal cord that has just been severely injured, so we knew we needed to find another way to quickly deliver an agent that would stop ATP from killing healthy motor neurons. Second, the compound we initially used, oxidized ATP, cannot be injected into the bloodstream because of its dangerous side effects," Nedergaard explained in the news release.

In the search for a compound that would thwart ATP attacks and could be administered intravenously, Nedergaard stumbled upon BBG.

An intravenous injection of BBG significantly reduced secondary injury in spinal cord-injured rats, which improved to the point of being able to walk again, although with a limp. There was a side effect, however. Injected rats had a blue tinge to their skin for a while.

While more study is needed, Nedergaard and longtime collaborator Dr. Steven Goldman, chair of the University of Rochester Department of Neurology, hope that BBG and related agents will yield new treatments for acute spinal cord injuries.

More information

The U.S. National Institutes of Health offers information on spinal cord injuries.



--Dennis Thompson



SOURCE: University of Rochester, news release, July 27, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Photo: New Data Show Gleevec(R) Halts Progression to Advanced Stages of Life-Threatening Form of Leukemia in Sixth Year of Treatment
2. Scripps research scientists find new genetic mutation that halts the development of lupus
3. Experimental Vaccine Halts Prostate Cancer in Mice
4. Manufacturer Halts Production of Blood Thinner Heparin
5. St. Jude finds signaling system that halts the growth of a childhood brain cancer
6. Surgical technique halts cell loss, Parkinsons researchers find
7. PA Department of Health Halts Admissions at Commonwealth Medical Center in Beaver County
8. Gastric Bypass Halts Diabetes in Obese Teens
9. Kellogg Halts Sales of Peanut Butter Crackers
10. FDA Halts New Applications From Indian Drug Makers Plant
11. Interferon does not slow or stop hepatitis C from worsening, study finds
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Blue Dye Halts Worsening Paralysis in Animal Study
(Date:3/1/2017)... ... 01, 2017 , ... Financial Recovery Group, Inc. (FRG), is proud to announce ... Nashville, Tenn. The company also is offering a special discount for those who attend ... year, brings together the brightest minds in the healthcare industry to share information on ...
(Date:3/1/2017)... ... March 01, 2017 , ... Look for a new collection of ... and Drift Roses. Star Roses and Plants is launching their new Bushel and ... Bushel and Berry Collection makes growing fresh fruit simple with a variety of easy-to-grow, ...
(Date:3/1/2017)... , ... March 01, 2017 , ... On January 27, ... Firm, filed a civil sex abuse lawsuit in the Circuit Court of Kanawha County, ... have only been identified by their initials. See L.B. and T.B. v. Seventh-Day Adventist ...
(Date:3/1/2017)... , ... March 01, 2017 , ... Award-winning medical group ... 25 medical mission trips in underdeveloped nations, averaging more than one trip per year ... article on the website features the details of his charitable work. Char ...
(Date:3/1/2017)... ... 2017 , ... NYC based Integrated practice Living Well Medical, a long time ... of Orthopaedic Surgeon Dr. Donald E. Heitman. Dr. Heitman is a native ... Bachelor of Science degree in biology. He then obtained his medical degree from New ...
Breaking Medicine News(10 mins):
(Date:3/1/2017)... Sun Chlorella Corp ., the California -based ... Non-GMO Project Verification and the launch of individual serving packets ... for the Natural Products Expo West trade show, March 10-12 ... Chlorella Corp. has announced the Non-GMO Project Verification logo is ... Sun Chlorella tablets, 250mg and 500mg (20/100-day supplies) ...
(Date:3/1/2017)... March 1, 2017  Integrated Modular Design ... design and implementation of pre-fabricated healthcare products ... room headwalls, seeks to lead the construction ... solutions. Fueled by their leading-edge ... of reducing construction timelines and project risk, ...
(Date:3/1/2017)... , March 1, 2017  Global biotherapeutics leader ... the largest ever Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) trial, ... T reatment with H izentra ® ).  ... the efficacy, safety and tolerability of two different doses ... (Immune Globulin Subcutaneous [Human]), compared with placebo, in the ...
Breaking Medicine Technology: